Alice Levine, MD
Endocrinology, Diabetes & Metabolism · New York, NYNPI 1750313953
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $18,800 of the $23,071 with a category attached, or 81.5%. 8 manufacturers reported payments, led by HRA Pharma RARE Diseases at 28.9% of the total.
Across 39 payments — averaging $591.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- HRA Pharma RARE Diseases$7K
- Neurocrine Biosciences, Inc.$7K
- Corcept Therapeutics$6K
- Arcutis Biotherapeutics, Inc.$3K
- Medtronic$375
- Chiesi USA, Inc.$300
- plus $334 from 2 others
Across 54 payments — averaging $3636.31 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Corcept Therapeutics$99K
- AbbVie$97K
What the payments were for
- Consulting fees$18,80081%
- Speaking & faculty fees$4102%
- Travel & lodging$2,1619%
- Food & beverage$1,7007%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| HRA Pharma RARE Diseases | 4 | $6,675 |
| Neurocrine Biosciences, Inc. | 11 | $6,608 |
| Corcept Therapeutics | 12 | $6,229 |
| Arcutis Biotherapeutics, Inc. | 1 | $2,550 |
| Medtronic | 3 | $375 |
| Chiesi USA, Inc. | 1 | $300 |
| Amgen | 6 | $224 |
| Sanofi | 1 | $110 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$23,071 in reported general payments places this provider in the 85th percentile of 804 endocrinology, diabetes & metabolism providers in New York.
See all endocrinology, diabetes & metabolism providers in New York →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Testosterone | 34 | $9,131 |
| Hydrocortisone | 151 | $4,634 |
| Eplerenone | 25 | $4,100 |
| SynthroidLevothyroxine Sodium | 44 | $3,707 |
| Ketoconazole | 17 | $3,435 |
| Levothyroxine Sodium | 128 | $733 |
| Cabergoline | 17 | $722 |
| Fludrocortisone Acetate | 14 | $622 |
| Spironolactone | 31 | $304 |
| Desmopressin Acetate | 22 | $139 |
| Calcitriol | 13 | $105 |
| Dexamethasone | 16 | $21 |
Paid to pharmacies, not to this prescriber.
Other endocrinology, diabetes & metabolism in New York
- John BilezikianNew York$809K
- Anastasios ManessisNew York$656K
- Jason BakerNew York$427K
- Brian LevyNew York$417K
- Stuart WeissNew York$275K
- Priya JaisinghaniNew York$239K
- Henry GinsbergNew York$161K
- Recaredo BerbanoNew York$146K
- Beverly TchangNew York$120K
- Shira EytanNew York$96K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.